S-1157-119
Passed Senate with an amendment by Unanimous Consent.
Sponsored by Tina Smith (D-MN)
What it does
This bill would require the Secretary of Health and Human Services (HHS), in consultation with the Departments of Defense and Veterans Affairs, to review and update federal programs related to lung cancer research, prevention, diagnosis, and treatment. The review would focus on identifying knowledge gaps in lung cancer research for women and populations with few known risk factors, and on improving screening rates among groups recommended by the U.S. Preventive Services Task Force. Within two years of enactment, HHS would be required to submit a report to Congress summarizing findings, any program changes already made, and recommendations for further changes.
Who benefits
Women with lung cancer or at risk of developing it, particularly those who do not fit traditional high-risk profiles (e.g., non-smokers). Underserved and low-screening-rate populations who may gain access to improved prevention and early detection programs. Researchers who may receive clearer federal direction and potential future funding priorities. Veterans and active-duty military personnel, whose health agencies are included in the review. Public health agencies that would receive updated federal strategic guidance.
Who is hurt
There are no direct, immediate costs imposed on any group. Federal agencies — primarily HHS, DoD, and VA — would bear administrative costs to conduct the review and produce the report. Competing research priorities within federal health budgets could face indirect pressure if the review leads to future funding shifts. No private sector entities face new mandates or restrictions under this bill.
Supporters argue
Supporters argue that lung cancer is the leading cause of cancer death among women, yet research has historically focused on male patients and smokers, leaving critical gaps in understanding environmental and genomic factors unique to women. They contend that low screening rates in recommended populations represent a preventable mortality burden, and that a structured interagency review is a low-cost, evidence-based first step toward closing those gaps and improving outcomes.
Opponents argue
Opponents argue that the bill creates a reporting mandate without appropriating dedicated funding, raising concerns that it may produce a report with little practical effect if agencies lack resources to act on its recommendations. They contend that existing agencies — NIH, CDC, and NCI — already have broad authority and ongoing programs to study lung cancer disparities, and that a new statutory review layer adds bureaucratic process without guaranteeing measurable improvements in research investment or patient outcomes.
Constitutional context
This bill falls squarely within Congress's authority under the Taxing and Spending Clause (Art. I, §8, cl. 1) and the Necessary and Proper Clause (Art. I, §8, cl. 18) to direct federal executive agencies to conduct reviews and report findings. No significant constitutional tension is present, as the bill imposes a directive on federal agencies rather than on states or private parties.
Checks and balances
The Executive Branch (HHS, DoD, VA) gains a directed research and review mandate; Congress retains oversight through the required report to the HELP, Energy and Commerce, and Appropriations Committees of both chambers, preserving the legislative branch's ability to act on findings.
Historical precedent
Congress has previously directed similar interagency reviews in disease-specific contexts, such as the National Breast and Cervical Cancer Early Detection Program (1990), which similarly targeted screening gaps in underserved women's populations.